Literature DB >> 17363465

Altered transit and bacterial overgrowth in the cystic fibrosis mouse small intestine.

Robert C De Lisle1.   

Abstract

Small intestinal bacterial overgrowth (SIBO) may play an important role in the gastrointestinal complications of cystic fibrosis (CF). This work explored two potential factors in development of SIBO in the CF (cftr(tm1UNC)) mouse: impaired Paneth cell innate defenses and altered gastrointestinal motility. Postnatal differentiation of Paneth cells was followed by Defcr, Lyzs, and Ang4 gene expression, and SIBO was measured by quantitative PCR of the bacterial 16S rRNA gene. Paneth cell gene expression was low in 4-day-old CF and wild-type (WT) mice and increased similarly in both groups of mice between 12 and 16 days. Peak Paneth cell gene expression was reached by 40 days of age and was less for Defcr and Lyzs in CF mice compared with WT, whereas Ang4 levels were greater in CF mice. SIBO occurred by postnatal day 8 in CF mice, which is before Paneth cell development. With the use of gavaged rhodamine-dextran to follow motility, gastric emptying in CF mice was slightly decreased compared with WT, and small intestinal transit was dramatically less. Since antibiotics improve weight gain in CF mice, their effects on gastric emptying and small intestinal transit were determined. Antibiotics did not affect gastric emptying or transit in CF mice but did significantly slow intestinal transit in WT mice, suggesting a potential role of normal microflora in regulating transit. In conclusion, small intestinal transit was significantly slower in CF mice, and this is likely a major factor in SIBO in CF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17363465     DOI: 10.1152/ajpgi.00548.2006

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  30 in total

1.  Cystic fibrosis mouse model-dependent intestinal structure and gut microbiome.

Authors:  Mark Bazett; Lisa Honeyman; Anguel N Stefanov; Christopher E Pope; Lucas R Hoffman; Christina K Haston
Journal:  Mamm Genome       Date:  2015-02-27       Impact factor: 2.957

2.  Fecal Human β-Defensin 2 in Children with Cystic Fibrosis: Is There a Diminished Intestinal Innate Immune Response?

Authors:  Chee Y Ooi; Tamara Pang; Steven T Leach; Tamarah Katz; Andrew S Day; Adam Jaffe
Journal:  Dig Dis Sci       Date:  2015-08-14       Impact factor: 3.199

3.  Effect of antibiotic treatment on fat absorption in mice with cystic fibrosis.

Authors:  Marjan Wouthuyzen-Bakker; Marcel J C Bijvelds; Hugo R de Jonge; Robert C De Lisle; Johannes G M Burgerhof; Henkjan J Verkade
Journal:  Pediatr Res       Date:  2012-01       Impact factor: 3.756

4.  Prevalence of Fecal Incontinence in Adults with Cystic Fibrosis.

Authors:  Alban Benezech; Nadine Desmazes-Dufeu; Karine Baumstarck; Michel Bouvier; Bérengère Coltey; Martine Reynaud-Gaubert; Véronique Vitton
Journal:  Dig Dis Sci       Date:  2017-10-30       Impact factor: 3.199

Review 5.  The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy.

Authors:  Millie Garg; Chee Y Ooi
Journal:  Curr Gastroenterol Rep       Date:  2017-02

6.  Critical design aspects involved in the study of Paneth cells and the intestinal microbiota.

Authors:  Michael T Shanahan; Ian M Carroll; Ajay S Gulati
Journal:  Gut Microbes       Date:  2013-12-20

7.  Sucrose co-administration reduces the toxic effect of lectin on gut permeability and intestinal bacterial colonization.

Authors:  Balamurugan Ramadass; Karol Dokladny; Pope L Moseley; Yatin R Patel; Henry C Lin
Journal:  Dig Dis Sci       Date:  2010-08-05       Impact factor: 3.199

Review 8.  The CF gastrointestinal microbiome: Structure and clinical impact.

Authors:  Geraint B Rogers; Michael R Narkewicz; Lucas R Hoffman
Journal:  Pediatr Pulmonol       Date:  2016-10

9.  Cystic fibrosis transmembrane conductance regulator knockout mice exhibit aberrant gastrointestinal microbiota.

Authors:  Susan V Lynch; Katherine C Goldfarb; Yvette K Wild; Weidong Kong; Robert C De Lisle; Eoin L Brodie
Journal:  Gut Microbes       Date:  2012-10-12

10.  Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype.

Authors:  Robert C De Lisle; Racquel Mueller; Eileen Roach
Journal:  BMC Gastroenterol       Date:  2010-09-15       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.